April 26 (Reuters) - Abbott Laboratories ABT.N:
NEW CLINICAL STUDY DATA SHOWCASE LONG-TERM, SUSTAINED BENEFITS OF ABBOTT'S VOLT™ PFA SYSTEM FOR PATIENTS WITH AFIB
ABBOTT LABORATORIES - VOLT PFA SYSTEM SHOWS STRONG 12-MONTH RESULTS
ABBOTT LABORATORIES - 83.5% PAF AND 58.1% PERSAF PATIENTS ARRHYTHMIA-FREE AFTER 12 MONTHS
ABBOTT LABORATORIES - ONLY 2.7% EXPERIENCED SAFETY ENDPOINT EVENT AFTER 12 MONTHS
Source text: ID:nPn4QqGp1a
Further company coverage: ABT.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.